A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer

Masanori Noguchi, Tatsuyuki Kakuma, Hirotsugu Uemura, Yasutomo Nasu, Hiromi Kumon, Yasuhiko Hirao, Fukuko Moriya, Shigetaka Suekane, Kei Matsuoka, Nobukazu Komatsu, Shigeki Shichijo, Akira Yamada, Kyogo Itoh

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Personalized peptide vaccination (PPV) combined with chemotherapy could be a novel approach for many cancer patients. In this randomized study, we evaluated the anti-tumor effect and safety of PPV plus low-dose estramustine phosphate (EMP) as compared to standard-dose EMP for HLA-A2- or -A24-positive patients with castration resistant prostate cancer. Patients were randomized into groups receiving either PPV plus low-dose EMP (280 mg/day) or standard-dose EMP (560 mg/day). After disease progression, patients were switched to the opposite regime. The primary end point was progression-free survival (PFS). We randomly assigned 28 patients to receive PPV plus low-dose EMP and 29 patients to receive standard-dose EMP. Nineteen events in the PPV group and 20 events in the EMP group occurred during the first treatment. Median PFS for the first treatment was 8.5 months in the PPV group and 2.8 months in the EMP group with a hazard ratio (HR) of 0.28 (95% CI, 0.14-0.61; log-rank P = 0.0012), while there was no difference for median PFS for the second treatment. The HR for overall survival was 0.3 (95% CI, 0.1-0.91) in favor of the PPV plus low-dose EMP group (log-rank, P = 0.0328). The PPV plus low-dose EMP was well tolerated without major adverse effects and with increased levels of IgG and cytotoxic-T cell responses to the vaccinated peptides. PPV plus low-dose EMP was associated with an improvement in PSA-based PFS as compared to the standard-dose EMP alone.

Original languageEnglish
Pages (from-to)1001-1009
Number of pages9
JournalCancer Immunology, Immunotherapy
Volume59
Issue number7
DOIs
Publication statusPublished - Jul 2010

Fingerprint

Estramustine
Subunit Vaccines
Castration
Prostatic Neoplasms
Phosphates
Vaccination
Peptides
Disease-Free Survival
HLA-A2 Antigen

Keywords

  • Immunotherapy
  • Peptide vaccine
  • Prostatic neoplasms
  • Randomized trial

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. / Noguchi, Masanori; Kakuma, Tatsuyuki; Uemura, Hirotsugu; Nasu, Yasutomo; Kumon, Hiromi; Hirao, Yasuhiko; Moriya, Fukuko; Suekane, Shigetaka; Matsuoka, Kei; Komatsu, Nobukazu; Shichijo, Shigeki; Yamada, Akira; Itoh, Kyogo.

In: Cancer Immunology, Immunotherapy, Vol. 59, No. 7, 07.2010, p. 1001-1009.

Research output: Contribution to journalArticle

Noguchi, M, Kakuma, T, Uemura, H, Nasu, Y, Kumon, H, Hirao, Y, Moriya, F, Suekane, S, Matsuoka, K, Komatsu, N, Shichijo, S, Yamada, A & Itoh, K 2010, 'A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer', Cancer Immunology, Immunotherapy, vol. 59, no. 7, pp. 1001-1009. https://doi.org/10.1007/s00262-010-0822-4
Noguchi, Masanori ; Kakuma, Tatsuyuki ; Uemura, Hirotsugu ; Nasu, Yasutomo ; Kumon, Hiromi ; Hirao, Yasuhiko ; Moriya, Fukuko ; Suekane, Shigetaka ; Matsuoka, Kei ; Komatsu, Nobukazu ; Shichijo, Shigeki ; Yamada, Akira ; Itoh, Kyogo. / A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. In: Cancer Immunology, Immunotherapy. 2010 ; Vol. 59, No. 7. pp. 1001-1009.
@article{826446c5e53c44439ffb0645b5991e2f,
title = "A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer",
abstract = "Personalized peptide vaccination (PPV) combined with chemotherapy could be a novel approach for many cancer patients. In this randomized study, we evaluated the anti-tumor effect and safety of PPV plus low-dose estramustine phosphate (EMP) as compared to standard-dose EMP for HLA-A2- or -A24-positive patients with castration resistant prostate cancer. Patients were randomized into groups receiving either PPV plus low-dose EMP (280 mg/day) or standard-dose EMP (560 mg/day). After disease progression, patients were switched to the opposite regime. The primary end point was progression-free survival (PFS). We randomly assigned 28 patients to receive PPV plus low-dose EMP and 29 patients to receive standard-dose EMP. Nineteen events in the PPV group and 20 events in the EMP group occurred during the first treatment. Median PFS for the first treatment was 8.5 months in the PPV group and 2.8 months in the EMP group with a hazard ratio (HR) of 0.28 (95{\%} CI, 0.14-0.61; log-rank P = 0.0012), while there was no difference for median PFS for the second treatment. The HR for overall survival was 0.3 (95{\%} CI, 0.1-0.91) in favor of the PPV plus low-dose EMP group (log-rank, P = 0.0328). The PPV plus low-dose EMP was well tolerated without major adverse effects and with increased levels of IgG and cytotoxic-T cell responses to the vaccinated peptides. PPV plus low-dose EMP was associated with an improvement in PSA-based PFS as compared to the standard-dose EMP alone.",
keywords = "Immunotherapy, Peptide vaccine, Prostatic neoplasms, Randomized trial",
author = "Masanori Noguchi and Tatsuyuki Kakuma and Hirotsugu Uemura and Yasutomo Nasu and Hiromi Kumon and Yasuhiko Hirao and Fukuko Moriya and Shigetaka Suekane and Kei Matsuoka and Nobukazu Komatsu and Shigeki Shichijo and Akira Yamada and Kyogo Itoh",
year = "2010",
month = "7",
doi = "10.1007/s00262-010-0822-4",
language = "English",
volume = "59",
pages = "1001--1009",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "7",

}

TY - JOUR

T1 - A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer

AU - Noguchi, Masanori

AU - Kakuma, Tatsuyuki

AU - Uemura, Hirotsugu

AU - Nasu, Yasutomo

AU - Kumon, Hiromi

AU - Hirao, Yasuhiko

AU - Moriya, Fukuko

AU - Suekane, Shigetaka

AU - Matsuoka, Kei

AU - Komatsu, Nobukazu

AU - Shichijo, Shigeki

AU - Yamada, Akira

AU - Itoh, Kyogo

PY - 2010/7

Y1 - 2010/7

N2 - Personalized peptide vaccination (PPV) combined with chemotherapy could be a novel approach for many cancer patients. In this randomized study, we evaluated the anti-tumor effect and safety of PPV plus low-dose estramustine phosphate (EMP) as compared to standard-dose EMP for HLA-A2- or -A24-positive patients with castration resistant prostate cancer. Patients were randomized into groups receiving either PPV plus low-dose EMP (280 mg/day) or standard-dose EMP (560 mg/day). After disease progression, patients were switched to the opposite regime. The primary end point was progression-free survival (PFS). We randomly assigned 28 patients to receive PPV plus low-dose EMP and 29 patients to receive standard-dose EMP. Nineteen events in the PPV group and 20 events in the EMP group occurred during the first treatment. Median PFS for the first treatment was 8.5 months in the PPV group and 2.8 months in the EMP group with a hazard ratio (HR) of 0.28 (95% CI, 0.14-0.61; log-rank P = 0.0012), while there was no difference for median PFS for the second treatment. The HR for overall survival was 0.3 (95% CI, 0.1-0.91) in favor of the PPV plus low-dose EMP group (log-rank, P = 0.0328). The PPV plus low-dose EMP was well tolerated without major adverse effects and with increased levels of IgG and cytotoxic-T cell responses to the vaccinated peptides. PPV plus low-dose EMP was associated with an improvement in PSA-based PFS as compared to the standard-dose EMP alone.

AB - Personalized peptide vaccination (PPV) combined with chemotherapy could be a novel approach for many cancer patients. In this randomized study, we evaluated the anti-tumor effect and safety of PPV plus low-dose estramustine phosphate (EMP) as compared to standard-dose EMP for HLA-A2- or -A24-positive patients with castration resistant prostate cancer. Patients were randomized into groups receiving either PPV plus low-dose EMP (280 mg/day) or standard-dose EMP (560 mg/day). After disease progression, patients were switched to the opposite regime. The primary end point was progression-free survival (PFS). We randomly assigned 28 patients to receive PPV plus low-dose EMP and 29 patients to receive standard-dose EMP. Nineteen events in the PPV group and 20 events in the EMP group occurred during the first treatment. Median PFS for the first treatment was 8.5 months in the PPV group and 2.8 months in the EMP group with a hazard ratio (HR) of 0.28 (95% CI, 0.14-0.61; log-rank P = 0.0012), while there was no difference for median PFS for the second treatment. The HR for overall survival was 0.3 (95% CI, 0.1-0.91) in favor of the PPV plus low-dose EMP group (log-rank, P = 0.0328). The PPV plus low-dose EMP was well tolerated without major adverse effects and with increased levels of IgG and cytotoxic-T cell responses to the vaccinated peptides. PPV plus low-dose EMP was associated with an improvement in PSA-based PFS as compared to the standard-dose EMP alone.

KW - Immunotherapy

KW - Peptide vaccine

KW - Prostatic neoplasms

KW - Randomized trial

UR - http://www.scopus.com/inward/record.url?scp=77953040440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953040440&partnerID=8YFLogxK

U2 - 10.1007/s00262-010-0822-4

DO - 10.1007/s00262-010-0822-4

M3 - Article

C2 - 20146063

AN - SCOPUS:77953040440

VL - 59

SP - 1001

EP - 1009

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 7

ER -